Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 17:00 save search
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-22 (Crawled : 17:00) - globenewswire.com
MRKR | $4.25 3.65% 3.52% 15K
|
Consumer Services
|
| O: 2.06%
H: 3.68%
C: 3.68%
conference cell therapeutics therapy
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 7.33%
H: 3.1%
C: -13.66%
first disease cell agreement therapy
FDA Decisions: Takeda's Immunoglobulin Therapy Approved for CDIP
Published: 2024-02-02 (Crawled : 17:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: -0.53%
H: 1.28%
C: 0.53%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
fda approved therapy
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -63.33%
H: 263.64%
C: 127.27%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
first genetic hospital treat therapy
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Published: 2023-12-08 (Crawled : 17:00) - globenewswire.com
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
COYA | $7.87 -6.75% -7.24% 54K
|
|
| O: 5.91%
H: 3.76%
C: -6.1%
sclerosis treatment collaboration commercialization therapy
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisVirtual Event to be held on November 29, 2023 at 4:15 p.m. ET
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
IMMX | $2.21 0.0% 64K
|
|
| O: 1.91%
H: 3.85%
C: 3.04%
nxc-201 candidate cell biopharma car-t therapy
FDA Greenlights First Therapy for Rare Cancer of the Nasopharynx
Published: 2023-10-30 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 1.52%
H: 0.18%
C: -1.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.39%
H: 0.79%
C: 0.64%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
fda rare cancer therapy
Peripheral Blood Mononuclear Cells Market Trends and Forecasts to 2027: Increasing Usage of Peripheral Blood Mononuclear Cells for Cell Therapy
Published: 2023-08-04 (Crawled : 17:00) - prnewswire.com
LZAGF | $563.5 -19.1% 6
|
Health Technology
|
| O: 0.55%
H: 1.13%
C: 0.51%
LZAGY | $55.65 0.02% 32K
|
Professional, Scientific, and T...
|
| O: 0.79%
H: 0.6%
C: -0.3%
CRL | $226.78 -0.34% 0.0% 410K
|
Commercial Services
|
| O: 0.38%
H: 0.0%
C: 0.0%
cell blood trends therapy market
Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS) in Sleep
Published: 2023-07-26 (Crawled : 17:00) - biospace.com/
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: -0.46%
H: 0.94%
C: 0.15%
health publication extension trial therapy results study
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
yescarta t-cell treatment care therapy
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.24%
H: 0.66%
C: 0.66%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.61%
H: 0.3%
C: 0.24%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.13%
C: -0.22%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.41%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.38%
H: 0.91%
C: 0.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.14%
H: 0.28%
C: 0.11%
report cancer global therapy growth market
Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Published: 2023-04-11 (Crawled : 17:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
association tumors cancer pipeline cell research preclinical meeting therapy
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Published: 2023-03-31 (Crawled : 17:00) - biospace.com/
IMMP | $2.25 2.27% 2.22% 90K
|
Health Technology
|
| O: 2.91%
H: 0.56%
C: -5.08%
lung positive cancer therapy
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
Published: 2023-03-30 (Crawled : 17:00) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 12.34%
H: 0.46%
C: -5.88%
drug candidate designation therapeutics therapy
Europe Cell and Gene Therapy Market Report 2023: Government, as Well as Industrial and Academic Financing and Collaboration Among Small and Large Biopharmaceutical Companies Bolsters Sector
Published: 2023-03-28 (Crawled : 17:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
europe companies report cell collaboration therapy market
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-03-08 (Crawled : 17:00) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: -0.37%
H: 4.49%
C: 2.62%
active collaboration trial therapeutics therapy cancer growth
Outlook on the Home Infusion Therapy Global Market to 2028 - Featuring Fresenius Kabi, JMS, PharmaScript, CareCentrix and PromptCare Among Others
Published: 2023-03-01 (Crawled : 17:00) - prnewswire.com
TRUMF | $16.928 -17.59% 1.9K
|
Health Technology
|
| O: -2.18%
H: 0.35%
C: -0.22%
TRUMY | $16.507 0.79% 34K
|
Manufacturing
|
| O: -2.81%
H: 0.79%
C: -0.62%
LIN | News | $446.32 -0.03% -0.02% 1.7M
|
Process Industries
|
| O: 0.5%
H: 1.74%
C: -0.01%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: -0.88%
H: 0.44%
C: -0.14%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.75%
H: 0.76%
C: -1.49%
OPCH | $31.08 0.58% 0.58% 2M
|
Health Services
|
| O: -0.59%
H: 2.9%
C: 2.62%
global home therapy market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.